beijing science sun pharmaceutical (300485.SZ) announcement, the company has initiated the confirmatory clinical trial of the drug addressing the National Medical Products Administration's "Notification on Initiating Confirmatory Clinical Trials of Sodium Oligomeric Proanthocyanidins for Ischemic Stroke Patients", and has completed the confirmatory clinical trial as required within three years. The product has obtained supplemental approval, and the instructions have been revised to indicate adaptation for patients with acute ischemic stroke.
Golden Ten Financial News APP reports that beijing science sun pharmaceutical (300485.SZ) has announced that the company has initiated the confirmatory clinical trial of the drug in accordance with the National Medical Products Administration's "Notification on Initiating Confirmatory Clinical Trials of Sodium Oligomeric Proanthocyanidins for Ischemic Stroke Patients" and related regulations. The company has completed the confirmatory clinical trial meeting current requirements within three years, submitted a supplemental application to the National Medical Products Administration's Drug Evaluation Center, obtained approval for the drug supplement application, revised the product manual, and updated the indication for use to include patients with acute ischemic stroke.
